News

Lexington Biosciences Comments on Recent Trading Activity

VANCOUVER, BC–(Nov 1, 2017) – Lexington Biosciences, Inc. (CSE: LNB) (CSE: LNB.CN) (CNSX: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington“) is issuing this press release at the request of the OTC Markets Group Inc. On October 17, 2017, the Company’s management became aware of certain promotional materials that were published by Techstock Insider that were purportedly paid for by

Read More

What Is Endothelial Function And Why Is It Important To My Health?

— by Jonathan Maltz Almost daily, my Google News stream is filled with articles about a new medical study that some food or medication that was once thought good for heart health is now to be avoided. I understand why many people feel confused and disoriented by the constant state of flux of dietary and

Read More

The Lexington News Issue #1 — Q3/2017

Welcome the the “Lexington News” where we hope to inform you on our ongoing efforts to develop our HeartSentry device into a revolutionary, simple and effective technology for personalized measurement and monitoring of vascular health. Aimed at detecting the potential for cardiovascular disease at its earliest stages, we are working to commercialize HeartSentry as part

Read More

Lexington Biosciences Announces Private Placement

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA – August 8 , 2017 – Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”), a development-stage medical device company operating within the healthcare industry, is pleased to announce a non-brokered private placement of up to

Read More

Lexington Biosciences Announces Closing of Private Placement

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES  VANCOUVER, BC – (July 28, 2017) – Lexington Biosciences, Inc. (CSE: LNB)( OTC: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company operating within the healthcare industry, is pleased to announce, further to its news release of

Read More

Lexington Biosciences Announces DTC Eligibility of LXGTF Common Shares on OTCQB

VANCOUVER, BC–(Jul 25, 2017) – Lexington Biosciences, Inc. (CSE: LNB) (CNSX: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company operating within the healthcare industry, is pleased to announce it has received processing approval from The Depository Trust Company (“DTC”) of New York, NY and is now DTC eligible. The Depository Trust Company (DTC) is a subsidiary

Read More

Lexington Biosciences Introduces Medical Advisory Board

Advisory team prepares to move HeartSentry through clinical studies VANCOUVER, BC–(Jul 20, 2017) – Lexington Biosciences, Inc. (CSE: LNB) (CNSX: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company operating within the healthcare industry, in preparation for the commencement of its HeartSentry clinical studies, today wishes to introduce the members of its Medical Advisory Board. The growing

Read More

1 2

Archives

Categories

Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News